Quick Takeaways
- LIGAND PHARMACEUTICALS INC filed SCHEDULE 13D for PELTHOS THERAPEUTICS INC. Common Stock, par value $0.0001 per share (CHRO).
- Disclosed ownership: 50%.
- Date of event: 01 Jul 2025.
LIGAND PHARMACEUTICALS INC - 01 Jul 2025 SCHEDULE 13D Report for PELTHOS THERAPEUTICS INC. Common Stock, par value $0.0001 per share (CHRO)
- Filing Manager
- LIGAND PHARMACEUTICALS INC
- Reporting Manager
- Ligand Pharmaceuticals Incorporated
- Symbol
- CHRO
- Shares outstanding
- 9,875,487 shares
- Disclosed Ownership
- 4,927,868 shares
- Ownership
- 50%
- Form type
- SCHEDULE 13D
- Filing time
- 03 Jul 2025, 16:05:07 UTC
- Date of event
- 01 Jul 2025
- Next filing
- 10 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"LIGAND PHARMACEUTICALS INC disclosed 50% ownership in PELTHOS THERAPEUTICS INC. Common Stock, par value $0.0001 per share (CHRO) on 01 Jul 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Jul 2025, 16:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated | 50% | 4,927,868 | 4,927,868 | 0 | /s/ Octavio Espinoza | Octavio Espinoza, Chief Financial Officer | 0000886163 |